Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice.

Semaphorin 3E (Sema3E) is a secreted molecule implicated in axonal path finding and inhibition of developmental and postischemic angiogenesis. Sema3E is also highly expressed in metastatic cancer cells, but its mechanistic role in tumor progression was not understood. Here we show that expression of Sema3E and its receptor Plexin D1 correlates with the metastatic progression of human tumors. Consistent with the clinical data, knocking down endogenous expression of either Sema3E or Plexin D1 in human metastatic carcinoma cells hampered their metastatic potential when injected into mice, while tumor growth was not markedly affected. Conversely, overexpression of exogenous Sema3E in cancer cells increased their invasiveness, transendothelial migration, and metastatic spreading, although it inhibited tumor vessel formation, resulting in reduced tumor growth in mice. The proinvasive and metastatic activity of Sema3E in tumor cells was dependent on transactivation of the Plexin D1-associated ErbB2/Neu oncogenic kinase. In sum, Sema3E-Plexin D1 signaling in cancer cells is crucially implicated in their metastatic behavior and may therefore be a promising target for strategies aimed at blocking tumor metastasis.

[1]  P. Comoglio,et al.  Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages , 2008, The Journal of experimental medicine.

[2]  D. Schadendorf,et al.  Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. , 2006, Pigment cell research.

[3]  G. Neufeld,et al.  The semaphorins: versatile regulators of tumour progression and tumour angiogenesis , 2008, Nature Reviews Cancer.

[4]  P. Comoglio,et al.  Signalling by semaphorin receptors: cell guidance and beyond. , 2000, Trends in cell biology.

[5]  Yuri Kotliarov,et al.  High-resolution global genomic survey of 178 gliomas reveals novel regions of copy number alteration and allelic imbalances. , 2006, Cancer research.

[6]  P. Comoglio,et al.  Plexin signaling hampers integrin‐based adhesion, leading to Rho‐kinase independent cell rounding, and inhibiting lamellipodia extension and cell motility , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  M. Hori,et al.  Dual roles of Sema6D in cardiac morphogenesis through region-specific association of its receptor, Plexin-A1, with off-track and vascular endothelial growth factor receptor type 2. , 2004, Genes & development.

[8]  J. Gutkind,et al.  Semaphorin 4D provides a link between axon guidance processes and tumor-induced angiogenesis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[9]  R. Pasterkamp,et al.  Semaphorin signaling: progress made and promises ahead. , 2008, Trends in biochemical sciences.

[10]  Thomas M. Jessell,et al.  Gating of Sema3E/PlexinD1 Signaling by Neuropilin-1 Switches Axonal Repulsion to Attraction during Brain Development , 2007, Neuron.

[11]  F. Cappuzzo,et al.  Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer , 2009, Oncogene.

[12]  L. Naldini,et al.  Generation of HIV-1 derived lentiviral vectors. , 2002, Methods in enzymology.

[13]  L. Tamagnone,et al.  Tyrosine phosphorylation in semaphorin signalling: shifting into overdrive , 2008, EMBO reports.

[14]  Akiyoshi Uemura,et al.  Inhibition of Semaphorin As a Novel Strategy for Therapeutic Angiogenesis , 2010, Circulation research.

[15]  Thomas M. Jessell,et al.  Semaphorin 3E and Plexin-D1 Control Vascular Pattern Independently of Neuropilins , 2005, Science.

[16]  J. Klingelhöfer,et al.  Transcription of a novel mouse semaphorin gene, M-semaH, correlates with the metastatic ability of mouse tumor cell lines. , 1998, Cancer research.

[17]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[18]  J. Epstein,et al.  PlexinD1 and semaphorin signaling are required in endothelial cells for cardiovascular development. , 2004, Developmental cell.

[19]  W. Leenders,et al.  Semaphorin 3E expression correlates inversely with Plexin D1 during tumor progression. , 2008, The American journal of pathology.

[20]  Carlos Cordon-Cardo,et al.  Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. Feldner,et al.  Cancer cell motility--on the road from c-erbB-2 receptor steered signaling to actin reorganization. , 2002, Experimental cell research.

[22]  G. Neufeld,et al.  Successful Inhibition of Tumor Development by Specific Class-3 Semaphorins Is Associated with Expression of Appropriate Semaphorin Receptors by Tumor Cells , 2008, PloS one.

[23]  M. Martín-Satué,et al.  Identification of semaphorin E gene expression in metastatic human lung adenocarcinoma cells by mRNA differential display , 1999, Journal of surgical oncology.

[24]  L. Tamagnone,et al.  Semaphorin signals in cell adhesion and cell migration: functional role and molecular mechanisms. , 2007, Advances in experimental medicine and biology.

[25]  Giorgio F. Gilestro,et al.  Proteolytic processing converts the repelling signal Sema3E into an inducer of invasive growth and lung metastasis. , 2005, Cancer research.

[26]  H. Katoh,et al.  Different Requirement for Rnd GTPases of R-Ras GAP Activity of Plexin-C1 and Plexin-D1* , 2009, Journal of Biological Chemistry.

[27]  Gerhard Christofori,et al.  EMT, the cytoskeleton, and cancer cell invasion , 2009, Cancer and Metastasis Reviews.

[28]  M. Kreuter,et al.  Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype. , 2004, The Journal of clinical investigation.

[29]  S. Offermanns,et al.  ErbB-2 and Met Reciprocally Regulate Cellular Signaling via Plexin-B1* , 2008, Journal of Biological Chemistry.

[30]  Yixin Wang,et al.  Novel Genes Associated with Malignant Melanoma but not Benign Melanocytic Lesions , 2005, Clinical Cancer Research.

[31]  L. Tamagnone,et al.  Semaphorin signaling in cancer cells and in cells of the tumor microenvironment – two sides of a coin , 2009, Journal of Cell Science.

[32]  Giorgio F. Gilestro,et al.  The Semaphorin 4D receptor controls invasive growth by coupling with Met , 2002, Nature Cell Biology.

[33]  W. Leenders,et al.  Plexin D1 is ubiquitously expressed on tumor vessels and tumor cells in solid malignancies , 2009, BMC Cancer.

[34]  G. Neufeld,et al.  Semaphorin-3F Is an Inhibitor of Tumor Angiogenesis , 2004, Cancer Research.

[35]  P. Carmeliet,et al.  The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment , 2008, The Journal of experimental medicine.

[36]  J. Minna,et al.  Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[37]  S. Offermanns,et al.  Plexin-B1/RhoGEF–mediated RhoA activation involves the receptor tyrosine kinase ErbB-2 , 2004, The Journal of cell biology.